



Medgenics, Inc.
('Medgenics' or the 'Company')

MEDGENICS CEO TO PRESENT EPODURE AT BIOMED CONFERENCE

Misgav, Israel and London, UK – June x, 2009 — Medgenics (AIM: MEDU/MEDG) today announced that the Company's Chief Executive Officer, Dr. Andrew Pearlman, will present at the ILSI-Israel BioMed Conference on June 15 at the David Intercontinental Hotel at 4:30 pm. Dr. Pearlman will discuss Medgenics' unique tissue-based platform technology for the sustained protein therapy, Biopump. Medgenics recently reported the successful demonstration of safety and efficacy of its first Biopump application, EPODURE for the treatment of anemia, having shown more than 7 months of sustained elevation of hemoglobin from a single treatment in patients with chronic kidney disease (CKD) in its ongoing Phase I/II clinical trial.

Medgenics' Biopump is a unique tissue-based platform technology that processes a toothpick sized sliver from the inner layer of the subject's skin to produce therapeutic proteins and is intended to provide sustained-action protein therapy for treatment of a range of chronic diseases, including Hepatitis C, hemophilia, and multiple sclerosis. The technology potentially offers a major advancement over today's protein therapy which involves frequent, costly, and painful bolus injections. A breakthrough in personalized medicine, the Biopump is intended to increase efficacy and safety, reduce side effects, and improve patient compliance and quality of life, as well as lower treatment costs, with promise to extend treatment to currently under-treated populations.

According to Dr. Pearlman, "We are pleased to be speaking at the Israel BioMed Conference to provide an overview of the continued and sustained positive trial results. The EPODURE Biopump represents the first of a line of Biopump products producing different proteins and designed to vastly improve the treatment of chronic diseases."

Medgenics intends to develop its technology for a variety of chronic conditions, initially focusing on anemia and hepatitis C, with the intent to bring it to market via multiple strategic alliances in the relevant therapeutic space. The Company is in active discussions with major potential strategic partners for one or more applications

ILSI-Biomed Israel 2009, 8th National Life Science & Technology Week, is the leading international conference covering the fast-growing field of innovation in the biomedical, health care and life sciences industries, is expected to attract over 6,000 local and international CEOs, experts, academics, scientists, researchers, venture capitalists, and angel investors.

For further information, contact:

Medgenics, Inc.

Phone: +972 4 902 8900

Dr. Andrew L. Pearlman

Phone: +1 646 284 8472

Grayling Global United States

Email: lwolf-creutzfeldt@hfgcg.com

Leslie Wolf-Creutzfeldt, Investor Relations

Ivette Almeida, Media Relations

Phone: +1 646 284 9455

NOTES TO EDITORS:

Medgenics, Inc. is a clinical-stage biopharmaceutical company developing its unique tissue-based Biopump platform technology to provide sustained-action protein therapy for the treatment of a range of chronic diseases.

Medgenics currently has two products in development based on this technology:

- EPODURE – producing erythropoietin (EPO) to treat anaemia
- INFRADURE – producing interferon-alpha (IFN- α) to treat hepatitis C

The Company has demonstrated proof of concept of the Biopump treatment procedure in a clinical trial of EPODURE in anemic subjects. The Company's Phase I/II clinical trial for its long-acting version of EPODURE, designed to produce and deliver a therapeutic dose of EPO steadily for seven months or more commenced in August 2008. Medgenics plans to follow with a clinical trial of INFRADURE.

Medgenics intends to develop its innovative products and bring them to market via multiple strategic partnerships with major pharmaceutical and/or medical device companies, starting with EPODURE and INFRADURE.

Beyond these, Medgenics plans to develop and/or out-license a pipeline of future Biopump products targeting the large and rapidly growing global protein therapy market, which is forecast to reach US \$87 billion by 2010. Other potential areas include multiple sclerosis (interferon- β), hemophilia (Factor VIII), pediatric growth hormone deficiency (human growth hormone) and diabetes (insulin).

Founded in 2000, Medgenics is a US-incorporated company with major operations in Misgav, Israel. Medgenics was admitted to the London AIM in December 2007 (AIM:MEDG and AIM:MEDU).

www.medgenics.com

CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements, which include all statements other than statements of historical fact, including (without limitation) those regarding the Company's financial position, business strategy, plans and objectives of management for future operations. These statements relate to future events, prospects, developments and strategies. Forward-looking statements are sometimes identified by their use of the terms and phrases such as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will," "will likely," "should," "could," "would," "may" or the negative of such terms and other comparable terminology. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may differ materially from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, the events described in the forward-looking statements contained in this release may not occur.